Sunflower Pharmaceutical Group Co (SZSE:002737) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Sunflower Pharmaceutical Group Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sunflower Pharmaceutical Group Co is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Sunflower Pharmaceutical Group Co's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Sunflower Pharmaceutical Group Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunflower Pharmaceutical Group Co's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunflower Pharmaceutical Group Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sunflower Pharmaceutical Group Co's Risk Assessment falls into.

Sunflower Pharmaceutical Group Co (SZSE:002737) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sunflower Pharmaceutical Group Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Sunflower Pharmaceutical Group Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunflower Pharmaceutical Group Co (SZSE:002737) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunflower Pharmaceutical Group Co Ltd (SZSE:002737) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

Welcome Road, 18 East Lake Road, Harbin High-Tech Industrial Development Zone, Harbin, Heilongjiang, CHN

Website

http://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co Ltd is engaged in pharmaceutical manufacturing, marketing, and scientific research. The company's product profile include Honeysuckle, Weikangling Granules, Autumn pear moisturizing cream, Vitamin AD drops, Pediatric paracetamol granules, Jianweixiaoshi tablets, Pediatric Chai Gui Antipyretic Granules, Pediatric cough syrup, Kang Fu anti-inflammatory suppository, Xiangsha Yangwei Pills, and others.

Executives

Liu Tian Wei	Director
Guan Yu Xiu	Director
Wu Guo Xiang	Executives
Ren Jing Shang	Directors, executives
Guan Yan Bin	Directors, executives
Wan Yun Guo	Executives
Tian Yan	Secretary Dong
Tan Chang	Executives
Zhang Quan	Director
Xu Qing Fen	Supervisors
Jiang Feng He	Supervisors
Wu Shu Hua	Director
Guan Yan Ling	Director
Zhou Jian Zhong	Executives

Sunflower Pharmaceutical Group Co (SZSE:002737) Headlines

No Headlines